Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Following Protest, FDA Accepts Pharmacyclics’ Xcytrin NDA

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

CEO tells “The Pink Sheet” DAILY data slated for release at upcoming medical conferences could further support approval.

You may also be interested in...



Pharmacyclics Taps Little-Used Regulatory Pathway For Xcytrin NDA

Firm’s decision to “file over protest” asks FDA to review NDA that received “refuse to file” letter in February.

Advisory Committee Votes Favorably On Dendreon’s Prostate Cancer Vaccine

Though questions remain, majority of members find Provenge has “substantial evidence” of efficacy.

Pharmacyclics Eyes Priority Review For NSCLC Treatment

CEO tells “The Pink Sheet” DAILY of the firm’s plan for detailing and ex-U.S. commercialization.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Keeping Track: Two Targeted Oncologics And A Novel SGLT-2 Inhibitor Clear US FDA

US Medicare Price Negotiation: Gaming FDA Approval Dates Could Delay Drug Selection

Rezafungin Review Highlights US FDA’s ‘Flexible Development' Approach For Antimicrobials

FDA Urged To Collaborate With USPTO On Orange Book Listings, Eliminate Patent Use Codes

See All
UsernamePublicRestriction

Register

PS065938

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By